Development of myelodysplastic syndrome and acute Myeloid Leukemia 15 years after hydroxyurea use in a patient with sickle cell anemia

Clinical Medicine Insights: Oncology

Volumn 6, Issue , 2012, Pages 149-152

  Baz, Walid ^a   Najfeld, Vesna ^b   Yotsuya, Matthew ^c   Talwar, Jotica ^c   Terjanian, Terenig ^c   Forte, Frank ^c  

^a Hematology/Oncology department   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

Author keywords

Acute myeloid leukemia; Hydroxyrea; Myelodysplastic syndrome

Indexed keywords

CD33 ANTIGEN; CD34 ANTIGEN; CD68 ANTIGEN; CYTARABINE; HYDROXYUREA; IDARUBICIN; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW BIOPSY; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHROMOSOME 17; CHROMOSOME 5; CHROMOSOME 7; DRUG MEGADOSE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARYOTYPE; LEUKEMIA REMISSION; MALE; MYELODYSPLASTIC SYNDROME; PANCYTOPENIA; RESPIRATORY FAILURE; SEPSIS; SICKLE CELL ANEMIA; SUBARACHNOID HEMORRHAGE;

EID: 84859717447     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S8810     Document Type: Article

References (19)

1. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289:1645-51.
2. Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 2008;148:939-55.
3. Montalembert M, Bégué P, Bernaudin F, et al. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease. Arch Dis Child. 1999;81:437-9.
4. Schultz WH, Ware RE. Malignancy in patients with sickle cell disease. Am J Hematol. 2003;74:249-53.
5. Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood. 2005;105:2685-90.
6. Al-Jam'a AH, Al-Dabbous IA, Al-Khatti AA, et al. Are we underestimating the leukemogenic risk of hydroxyurea. Saudi Med J. 2002;23:1411-3.
7. Rauch A, Borromeo M, Ghafoor A, et al. Leukemogenesis of hydroxyurea in the treatment of sickle cell anemia. Blood. 1999;94:415a (suppl 1;abstr 1840).
8. Wilson S. Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea. Ann Intern Med. 2000;133:925-6.
9. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115:2354-63.
10. Stewart AJ, Jones RD. Pseudo-Gaucher cells in myelodysplasia. J Clin Pathol. 1999;52:917-8.
11. Rosenbloom BE, Weinreb NJ, Zimran A, et al. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood. 2005;105:4569-72.
12. Swolin B, Rödjer S, Westin J. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature. Ann Hematol. 2008;87:467-74.
13. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102:43-52.
14. Kantarjian HM, Keating MJ, Walters RS, et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol. 1986;4:1748-57.
15. Merlat A, Lai JL, Sterkers Y, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia. 1999;13:250-7.
16. Soenen V, Preudhomme C, Roumier C, et al. 17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood. 1998;91:1008-5.
17. Thoennissen NH, Krug UO, Lee DH, et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2010;115:2882-90.
18. Beer PA, Delhommeau F, Lecouedic JP, et al. Two routes to leukemic transformation following a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2010;115:2891-900.
19. Strouse JJ, Lanzkron S, Beach MC, et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics. 2008;122:1332-42.